The identity verification firm reports 18% year-over-year revenue growth in Q3, exceeding expectations, alongside leadership changes. Mitek Systems announced a fiscal 2026 revenue target of $195M to $200M, reflecting confidence in sustained growth. The company reported 18%
The company targets debt reduction post-IPO, aiming for $63M in annualized interest savings amid 14.5% revenue growth. Csquare Inc. updated its revenue outlook to a range of $1.13 billion to $1.17 billion for the upcoming period, citing consistent business performance. The
VSE Corporation outlines aggressive growth targets following record profitability and strategic acquisitions in Q2 2026. VSE Corporation expects revenue to climb 61%-64% by Q2 2026, driven by the integration of recent acquisitions and operational efficiencies. The company
Etsy raises its Q3 2026 gross merchandise sales outlook to $2.53B-$2.58B and announces a $2B share repurchase plan. Etsy updated its Q3 2026 gross merchandise sales (GMS) guidance to a range of $2.53 billion to $2.58 billion, reflecting stronger marketplace performance. Th
The biotech firm targets over half of new prescriptions for its drug MYQORZO by year-end 2026 amid strong Q2 2026 commercial performance. Cytokinetics aims to capture more than 50% of new-to-brand prescriptions for MYQORZO by the end of 2026. The target follows robust comm
Korean equities reverse gains on Hormuz shipping concerns The Korean stock market initially rallied but ended with significant losses due to reports of a potential Hormuz shipping restriction and renewed Houthi activity against Saudi Arabia. The Japanese market saw
The company maintains its $10M-$15M revenue outlook for 2026 while forecasting improved profitability margins. MicroVision expects its gross margin to reach 40%-45% in 2026, reflecting a focus on cost efficiency and scalability. The projection aligns with its previously st
The company projects revenue growth as it launches a new strategic phase following strong fiscal 2026 performance. Covista announced a fiscal 2027 revenue forecast of $2.05 billion to $2.09 billion during its Q4 earnings call. The guidance follows the company exceeding its
CytomX Therapeutics targets H1 2027 for Varseta-M registrational study start, projecting cash runway into late 2028. CytomX Therapeutics announced plans to initiate a registrational trial for Varseta-M, its EpCAM-targeting antibody drug conjugate, in the first half of 2027
The biotech firm raised its full-year revenue outlook after Q2 revenue reached $151 million, including a $1.6 million settlement item. 10x Genomics increased its 2026 revenue guidance to a range of $610 million to $630 million, citing sustained demand for its Atera systems
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.